← VisionWave Holdings, Inc. (VWAV) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
VisionWave Holdings, Inc. (VWAV)
Services-Prepackaged Software · market cap $111M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
13
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
VisionWave Holdings, Inc. (VWAV) is a $111M market-cap ophthalmology-focused company with a broad pipeline spanning Phase 2 and Phase 3 clinical assets across multiple ocular indications, including Stargardt Disease, geographic atrophy, Fuchs endothelial dystrophy, dry eye disease, and others. The company is classified under prepackaged software services — a notable sector mismatch suggesting either a legacy classification or a holding/platform structure — and reported a net loss of approximately $7M in 2025 with no disclosed revenue. No near-term catalysts are on the public calendar and financial details including cash position and runway are undisclosed.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Emixustat | Phase 3 | Stargardt Disease |
| Drug: GB-102 | Phase 2 | Neovascular Age-Related Macular Degeneration |
| SHJ002/Vehicle | Phase 2 | Dry Eye Disease |
| Netarsudil Ophthalmic Solution | Phase 3 | Fuchs Endothelial Dystrophy |
| EV06 Ophthalmic Solution | Phase 2 | Presbyopia |
| Riboflavin | Phase 2 | Keratoconus |
| emixustat hydrochloride | Phase 2 | Proliferative Diabetic Retinopathy |
| rebamipide 2% ophthalmic suspension | Phase 3 | Dry Eye Syndromes |
| OPA-6566 | Phase 2 | Primary Open-angle Glaucoma |
| ACU-4429 | Phase 3 | Geographic Atrophy |
| GB-102 | Phase 2 | Diabetic Macular Edema |
| SHJ002 | Phase 2 | Myopia, Progressive |
| Prednisolone acetate | Phase 2 | Fuchs' Dystrophy |
Price & technical context
3-month
-42.1%
6-month
-51.6%
12-month
-66.7%
52-wk range
$2.30–$15.00
vs 50-day MA
-23.2%
vs 200-day MA
-49.4%
Realized vol
228.3%
Max drawdown
-84.7%
Daily closes through 2026-06-25. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VWAV (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.